Edition:
United Kingdom

Nichi-Iko Pharmaceutical Co Ltd (4541.T)

4541.T on Tokyo Stock Exchange

1,700JPY
5:02am GMT
Change (% chg)

¥10 (+0.59%)
Prev Close
¥1,690
Open
¥1,689
Day's High
¥1,706
Day's Low
¥1,687
Volume
138,700
Avg. Vol
382,109
52-wk High
¥1,895
52-wk Low
¥1,598

Chart for

About

Nichi-Iko Pharmaceutical Co., Ltd., a Japan-based company together with its subsidiaries, is principally engaged in the manufacture and sale of generic pharmaceutical products and other medical products. The Company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its... (more)

Overall

Beta: 0.70
Market Cap(Mil.): ¥107,130.20
Shares Outstanding(Mil.): 60.66
Dividend: 15.00
Yield (%): 1.70

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Nichi-Iko Pharmaceutical to start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko"

* Says it will start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" on Nov. 29

28 Nov 2017

BRIEF- Nichi-Iko Pharmaceutical says merger with wholly owned unit

Oct 2Nichi-Iko Pharmaceutical Co Ltd * Says it merged with a wholly owned unit, on Oct. 1 Source text in Japanese:https://goo.gl/Zi3Hxh Further company coverage: (Beijing Headline News)

02 Oct 2017

BRIEF-Nichi-Iko Pharmaceutical and unit says marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" and "AYUMI"

* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" from the Ministry of Labour, Health, and Welfare on Sept. 27

27 Sep 2017

Earnings vs. Estimates